Delivery Order SPE2DB22D1103-SPE2DB25FTDR8

Award Date 1/2/25
Potential Completion Date 1/3/25
Potential Value $7.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,335.74, is a firm fixed-price delivery order for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $19,613.44 firm fixed-price delivery order contract is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of January 6, 2025 and there is no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,178.62 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 1, 2023 and was awarded on October 31, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,992.75 firm fixed-price delivery order is for the supply of the medication GEMTESA 75 MG TABLET 90S. The contract has an ultimate completion date of August 9, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,678.53, is a delivery order for the pharmaceutical product GEMTESA 75 MG TABLET 30S. The contract has an ultimate completion date of April 10, 2024 and a firm fixed price pricing type. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,367.17 firm fixed-price delivery order is for the provision of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of December 2, 2024 and was awarded on November 29, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,186.41 Firm Fixed Price delivery order is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of October 16, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,497.87 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of April 19, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,755.42, is for the delivery of GEMTESA 75 MG TABLET 90S, a medical product. The contract is a firm fixed-price agreement with an ultimate completion date of January 3, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,015.21 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of May 30, 2024. AmerisourceBergen holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB25FTDR8
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,868.69, is a Firm Fixed Price Delivery Order for the pharmaceutical product GEMTESA 75 MG TABLET 90S. The award has an ultimate completion date of January 3, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award does not have a set-aside designation, indicating open competition.

Generated 4/3/25, 10:16 AM